November 2016, Vol. 5, No. 9

← Back to Issue

Providing Practical Information to Promote Targeted, Effective, and Personalized Treatments

Al B. Benson III, MD, FACP, FASCO

Letter to Our Readers

Dear Colleague,

With every issue, all of us on the editorial staff of Personalized Medicine in Oncology (PMO) strive to provide members of multidisciplinary oncology teams practical information about research advances and improvements within the personalized medicine spectrum that allow for more targeted and effective treatments.

We are pleased to offer a continuing education opportunity entitled “Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.” This activity explores the role of immune checkpoint inhibitors in the treatment of an increasing range of solid tumors and hematologic malignancies as well as the use of predictive molecular biomarkers. In addition, it examines the value proposition associated with the use of immune checkpoint inhibitors in terms of costs and management of adverse events.

We offer insights from Steven Sandler, MD, on the 2016 revisions to the World Health Organization’s classification of myeloid neoplasms and acute leukemia in his article entitled “Understanding the Current Classification Criterion and Prognosis Models for the Myelodysplastic Syndromes and Dysplastic Cytopenias of Undetermined Significance as a Paradigm for Personalized Medicine.”

To enhance reader learning, we present a case study from Dr Steven Sorscher and colleagues entitled “A One Pathway ‘Two-Different Hit’ Hypothesis: Symbiosis in Transformation.” The authors discuss a patient with pancreatic cancer and PALB2 and BRCA2 alterations.

Coverage of important topics from the European Society for Medical Oncology is included in this issue, as well as an article from the Palliative Care in Oncology Symposium on managing immune-related toxicities.

Thank you for your readership. On behalf of the Editorial Board, it is our pleasure to serve you well in our quest to implement the new processes of personalized medicine.

Sincerely,

Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology

ESMO 2016 - November 10, 2016

Quality of Life Improved with Nivolumab versus Chemotherapy

In recent years, the cancer patient’s experience has been recognized as an important factor in determining the value of a treatment. According to patient reports, their quality of life (QOL) remained stable on the immunotherapy nivolumab, whereas it significantly deteriorated on chemotherapy, as shown in an analysis of a phase [ Read More ]

ESMO 2016 - November 10, 2016

Potentially Practice-Changing: Ribociclib/Letrozole Combo in Advanced Breast Cancer

The addition of the selective CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival (PFS) in hormone receptor–positive (HR+) advanced breast cancer. Compared with letrozole alone, the combination of ribociclib/letrozole improved PFS by 44%. These results from the phase 3 MONALEESA-2 trial were presented at the European Society for Medical [ Read More ]